Seroconversion to Multiple Islet Autoantibodies and Risk of Progression to Diabetes in Children

Anette G. Ziegler, MD
Marian Rewers, MD, PhD
Olli Simell, MD, PhD
Tuula Simell, MPH, PhD
Johanna Lempainen, MD, PhD
Andrea Steck, MD
Christiane Winkler, PhD
Jorma Ilonen, MD, PhD
Riitta Veijola, MD, PhD
Mikael Knip, MD, PhD
Ezio Bonifacio, PhD
George S. Eisenbarth, MD, PhD†

**Importance** Type 1 diabetes usually has a preclinical phase identified by circulating islet autoantibodies, but the rate of progression to diabetes after seroconversion to islet autoantibodies is uncertain.

**Objective** To determine the rate of progression to diabetes after islet autoantibody seroconversion.

**Design, Setting, and Participants** Data were pooled from prospective cohort studies performed in Colorado (recruitment, 1993-2006), Finland (recruitment, 1994-2009), and Germany (recruitment, 1989-2006) examining children genetically at risk for type 1 diabetes for the development of insulin autoantibodies, glutamic acid decarboxylase 65 (GAD65) autoantibodies, insulinoma antigen 2 (IA2) autoantibodies, and diabetes. Participants were all children recruited and followed up in the studies (Colorado, 1962; Finland, 8597; Germany, 2818). Follow-up assessment in each study was concluded by July 2012.

**Main Outcomes and Measures** The primary analysis was the diagnosis of type 1 diabetes in children with 2 or more autoantibodies. The secondary analysis was the diagnosis of type 1 diabetes in children with 1 autoantibody or no autoantibodies.

**Results** Progression to type 1 diabetes at 10-year follow-up after islet autoantibody seroconversion in 585 children with multiple islet autoantibodies was 69.7% (95% CI, 65.1%-74.3%), and in 474 children with a single islet autoantibody was 14.5% (95% CI, 10.3%-18.7%). Risk of diabetes in children who had no islet autoantibodies was 0.4% (95% CI, 0.2%-0.6%) by the age of 15 years. Progression to type 1 diabetes in the children with multiple islet autoantibodies was faster for children who had islet autoantibody seroconversion younger than age 3 years (hazard ratio [HR], 1.65 [95% CI, 1.30-2.09; P < .001]; 10-year risk, 74.9% [95% CI, 69.7%-80.1%]) vs children 3 years or older (60.9% [95% CI, 51.5%-70.3%]); for children with the human leukocyte antigen (HLA) genotype DR3/DR4-DQ8 (HR, 1.35 [95% CI, 1.09-1.68; P = .007]; 10-year risk, 76.6% [95% CI, 69.2%-84.4%]) vs other HLA genotypes (66.2% [95% CI, 60.2%-72.2%]); and for girls (HR, 1.28 [95% CI, 1.04-1.58; P = .02]; 10-year risk, 74.8% [95% CI, 68.0%-81.6%]) vs boys (65.7% [95% CI, 59.3%-72.1%]).

**Conclusions and Relevance** The majority of children at risk of type 1 diabetes who had multiple islet autoantibody seroconversion progressed to diabetes over the next 15 years. Future prevention studies should focus on this high-risk population.
Several intervention studies have been undertaken in which eligibility is based on these markers. However, follow-up studies of individuals identified by cross-sectional screening cannot determine a true progression rate because they do not identify when a patient develops islet autoantibodies. Importantly, patients who progress rapidly from initial seroconversion to type 1 diabetes are missed in these studies.

Recently, 3 long-term studies in Germany, Finland, and Colorado have followed up children from birth and have an opportunity to determine both the age of seroconversion and the age at diabetes onset. These studies have shown that islet autoantibody seroconversion is relatively common in the first years of life. However, information about diabetes progression rates after seroconversion and the factors that affect the rate of progression is still limited. In this study, we pooled data from these 3 studies to estimate rates of disease progression and associated characteristics based on islet autoantibody status.

METHODS
Study Populations
All 3 studies were approved by institutional review boards. Written informed consent was obtained from parents or legal guardians for each participant.

Data from prospective birth cohort studies were combined for this analysis. The Colorado Diabetes Autoimmunity Study in the Young (DAISY) study, the Finnish Type 1 Diabetes Prediction and Prevention (DIPP) study, and the German BABYDIAB and BABYDIET studies were undertaken to investigate the natural history of islet autoimmunity and type 1 diabetes in children with increased genetic risk of type 1 diabetes. The studies were homogeneous in the definition of islet autoantibody seroconversion and type 1 diabetes and were similar in the inclusion of at-risk populations and follow-up design. Additionally, the DIPP study included an intervention to evaluate efficacy of intranasally administered insulin to reduce progression to diabetes in children with multiple islet autoantibodies, and the high-risk study, BABYDIET, included investigation of whether delay of exposure to gluten could reduce the risk of developing islet autoantibodies in children who are genetically at risk. These interventions failed to show an effect on the progression rate to diabetes and islet autoimmunity, and all children underwent follow-up after completion of the intervention within a natural history protocol.

The DAISY study recruited newborns and infants at risk of type 1 diabetes with human leukocyte antigen (HLA) DR/DQ genotypes born at St Joseph’s Hospital (Denver) from 1993 through 2006 and also children who had a first-degree relative with type 1 diabetes who was treated at the Barbara Davis Center, as previously described. Children enrolled in the study were scheduled for follow-up and islet autoantibody measurement at age 9, 15, and 24 months and yearly thereafter or every 3 to 6 months if autoantibody positive.

The DIPP study recruited newborns and infants at risk of type 1 diabetes with HLA DR/DQ genotypes from 3 clinical centers in Oulu, Tampere, and Turku from 1994 through 2009, as previously described. Children recruited from Oulu and Tampere were scheduled for follow-up and islet autoantibody measurement at age 3, 6, 12, 18, and 24 months and yearly thereafter, and children recruited in Turku were scheduled for the same follow-up procedures every 3 months until 2 years of age and every 6 months thereafter.

The BABYDIAB study recruited newborns and infants who had a mother or father with type 1 diabetes (1989-2000), and the BABYDIET study recruited newborns who had a first-degree relative with type 1 diabetes (2000-2006), as previously described. Children recruited into the BABYDIAB or BABYDIET studies were scheduled for follow-up and islet autoantibody measurement at age 9 months, 2 years, and every 3 years thereafter. BABYDIET scheduled 150 high-risk children participating in dietary intervention for follow-up and islet autoantibody measurements every 3 months until 3 years of age and yearly thereafter. Children considered to be at high risk were those with the HLA genotypes DR3/4-DQ8, DR4-DQ8/DR4-DQ8, or DR3/3 and children who had 2 or more first-degree relatives with type 1 diabetes.

All 3 studies measured autoantibodies against insulin, glutamic acid decarboxylase 65 (GAD65), and insulinoma antigen 2 (IA2) from multiple samples taken throughout childhood to identify the age of islet autoantibody seroconversion. Outcome in the prospective studies was the development of islet autoantibodies with subsequent follow-up for type 1 diabetes. Islet autoantibody seroconversion was defined as a positive test result for 1 or more islet autoantibodies in at least 2 serial samples or in 1 sample followed by the development of diabetes before the next follow-up visit. All children with islet autoantibody seroconversion (2 patients) were included in our study analyses. Children who did not reach islet autoantibody seroconversion but had at least 1 sample tested from scheduled visits in either Colorado or Germany or at least 3 samples tested in the Finnish study (which had more scheduled visits) were included in our study analyses and were identified as islet autoantibody negative. The primary analysis included those who developed multiple autoantibodies. The secondary analysis included children with only 1 autoantibody or no autoantibodies. Autoantibodies against insulin, GAD65, and IA2 were determined in all follow-up samples with previously described methods. Zinc transporter 8 autoantibodies were additionally measured in children with islet autoantibodies from the Colorado and Germany cohorts and progression to diabetes in children with 2 or more of the 4 islet autoantibodies reported separately.
The primary analysis was diabetes diagnosed using World Health Organization and American Diabetes Association criteria.14 Children participated in follow-up visits until July 2012 or until the development of diabetes. Families were asked to report the occurrence of diabetes symptoms. In children with islet autoantibodies, an annual oral glucose tolerance test was performed. Diabetes onset was defined as unequivocal hyperglycemia with acute metabolic decompensation; the observation on at least 2 occasions of a 2-hour plasma glucose greater than 200 mg/dL (to convert to millimoles per liter, multiply by 0.0555) after an oral glucose test; or a random blood glucose concentration greater than 200 mg/dL accompanied by unequivocal symptoms. Since 1997, fasting blood glucose greater than 126 mg/dL on 2 occasions was added to the diabetes diagnosis criteria.14 Families of children who dropped out of the study or refused to provide blood samples or perform oral glucose tolerance tests were regularly contacted by telephone and were asked if the child had developed diabetes. In case of loss to follow-up, local diabetes registries or cohort studies were used as a second source to obtain information on diabetes development of former study participants. Children who had not developed diabetes and could not be contacted for 3 or more years were considered lost to follow-up.

Statistical Analysis

Time-to-event analysis was used to examine progression from seroconversion to diabetes. Kaplan-Meier estimates were used to calculate risk and to compare probabilities of type 1 diabetes in children stratified by country. The time-to-event was calculated from the age at seroconversion to the age at diagnosis of diabetes or the age at last follow-up. For children who did not develop islet autoantibodies, the median age of seroconversion in children with multiple islet autoantibodies (2.1 years) was used as a proxy for seroconversion age. Risk was presented at 5-, 10-, and 15-year follow-up visits after seroconversion (or proxy), and by 15 years of age. The log-rank test was used to compare categories in the Kaplan-Meier estimates.

Associations between age at seroconversion, sex, HLA genotype, number of islet autoantibodies, and type 1 diabetes risk were analyzed by the Cox proportional hazards regression model, assessing hazard ratios (HRs) with corresponding 95% confidence intervals. Children with missing data were not included in the model. Proportionality in the model was tested by generating time-dependent covariates through creating and including interactions of the predictors and the logarithm of survival time. If any of the time-dependent covariates were significant, those predictors were not considered proportional. In order to account for potential heterogeneity among the 3 cohorts, we included random effects for the different studies in the Cox model, thus using a meta-analytical approach for individual participant data, which accounts for the variance both within and between studies. Specifically, a shared frailty model for clustered data with normally distributed random effects was calculated with residual maximum likelihood estimation of the variance parameter.

The age at islet autoantibody seroconversion and the follow-up time after seroconversion were compared between cohorts using the Mann-Whitney U test. Comparisons of islet autoantibody status, HLA genotype, and sex among children who developed diabetes within 10 years and those who did not develop diabetes for more than 10 years was performed by the Fisher exact test. For all analyses, a 2-tailed P value of .05 was considered significant. All statistical analyses were performed using SAS, version 9.2 (SAS Institute).

RESULTS

Altogether, 13,377 children enrolled into the prospective studies in Colorado (n = 1962), Finland (n = 8597), and Germany (n = 2818) were tested for autoantibodies against insulin, GAD65, and IA2 at scheduled visits. A total of 1059 children (7.9%) seroconverted to islet autoantibody-positive (460; 43.4% girls), and 12,318 children (92.1%) remained islet autoantibody-negative (5807; 47.1% girls) (Table 1). Of the 1059 children with islet autoantibodies, 585 children (4.4%) developed multiple islet autoantibodies (249; 42.6% girls), including 69 (3.5%) from Colorado, 399 (4.6%) from Finland, and 117 from (4.2%) Germany. The remaining 474 children (3.5%) were single islet autoantibody-positive; 71 (3.6%) in Colorado, 293 (3.4%) in Finland, 110 (3.9%) in Germany. A total of 428 children developed diabetes, including 25 children who progressed to diabetes without an islet autoantibody-positive sample prior to diabetes onset (8 in Colorado, 13 in Finland, and 4 in Germany). Diabetes risk by 15 years of age was 0.4% (95% CI, 0.2%-0.6%) in children with no autoantibodies, 12.7% (95% CI, 8.9%-16.5%) in children with a single islet autoantibody, 61.6% (95% CI, 53.7%-70.2%) in children with 2 islet autoantibodies, and 79.1% (95% CI, 73.3%-85%) in children with 3 islet autoantibodies (Figure 1).

Children With Multiple Islet Autoantibodies

The median age at seroconversion in the 585 children with multiple islet autoantibodies was 2.1 years (range, 0.5-16 years; interquartile range [IQR], 1.3-4.1 years), and was slightly higher in children from Colorado (3.1 years) than in children from Finland (2.0 years) and Germany (2.1 years) (P = .003).

Median follow-up time after seroconversion in children with multiple islet autoantibodies was 4.5 years (range, 0.19-6.6 years; IQR, 2.3-7.2 years; 3021 total follow-up years), and was slightly shorter in children from Finland (3.9 years) than in children from Colorado (5.6 years) and Germany (5.3 years) (P = .04).

A total of 355 children (60.7%) with multiple islet autoantibodies progressed to diabetes (HR compared with
CIRCULATING ISLET ANTIBODIES AND DIABETES IN CHILDREN

children with no autoantibodies, 395.6 [95% CI, 263.2–594.4], P < .001) at a median follow-up time after seroconversion of 3.5 years (IQR, 1.7–6.0 years), and a median age of 6.1 years (IQR, 3.5–9.2 years). Progression to diabetes after seroconversion was 43.5% (95% CI, 39.4%–47.8%) at 5-year follow-up, 69.7% (95% CI, 65.1%–74.3%) at the 10-year follow-up, and 84.2% (95% CI, 77.7%–89.7%) at the 15-year follow-up (FIGURE 2). Ten-year risks were not significantly different (P = .08 for the log-rank test) across the 3 cohorts: Colorado, 70.8% (95% CI, 57.3%–83.2%); Finland, 71.9% (95% CI, 66.2%–77.3%); and Germany, 61.7% (95% CI, 51.3%–72.2%).

After 10 years of follow-up, 331 children with multiple autoantibodies had developed diabetes; 70 did not develop diabetes, and 184 had not reached 10 years of follow-up. Girls were more frequent among the children who developed diabetes within 10 years (151 of 331) than children who did not develop diabetes (21 of 70, P = .02). In the multivariable Cox proportional hazards regression model (TABLE 2), faster progression to diabetes after seroconversion was associated with younger age at seroconversion (<3 years vs ≥3 years; HR, 1.65 [95% CI, 1.30–2.09], P < .001; 10-year risk of 74.9% [95% CI, 69.7%–80.1%] at age <3 years vs 60.9% [95% CI, 51.5%–70.3%] at age ≥3 years); HLA DR3/DR4-DQ8 genotype (HR, 1.35 [95% CI, 1.09–1.68], P = .007; 10-year risk of 76.6% [95% CI, 69.2%–84.0%] for HLA DR3/4-DQ8 vs 66.2% [95% CI, 60.2%–72.2%] for other HLA genotypes); and female sex (HR, 1.28 [95% CI, 1.04–1.58], P = .002; 10-year risk of 74.8% [95% CI, 68.0%–81.6%] for girls vs 65.7% [95% CI, 59.3%–72.1%] for boys). Within the subgroup of children with 2 islet autoantibodies, progression to diabetes within 10 years after seroconversion was increased in children with the combination of autoantibodies against insulin and IA2 (83.6% [95% CI, 70.1%–97.1%]) than in children with autoantibodies against insulin and GAD65 (55.1% [95% CI, 41.4%–68.8%], P = .006) and children with autoantibodies against GAD65 and IA2 (62.0% [95% CI, 43.3%–90.7%], P = .002) (FIGURE 3A). In the Colorado and German cohorts, the addition of zinc transporter 8 autoantibodies identified 7 more children (6%) who progressed to diabetes but did not substantially alter the estimates of diabetes progression: 10-year risk of 68.9% (95% CI, 55.5%–82.3%) in Colorado and 65.3% (95% CI, 54.9%–75.7%) in Germany.

**Children With a Single Islet Autoantibody**

The median age of seroconversion in the 474 children with a single islet autoantibody was 4.8 years (range, 0.5–18.4 years; IQR, 2.1–7.7 years). Of these, 206 had insulin autoantibodies; 231, GAD65 autoantibodies; and 37, IA2 autoantibodies. The median follow-up time after seroconversion in children with a single islet autoantibody was 5.5 years (range, 0.1–16.5 years; IQR, 2.6–8.5 years; 2779 total follow-up years).

**Table 1. Description of Study Population**

<table>
<thead>
<tr>
<th>Autoantibody Status</th>
<th>All / Total (%) of Participants</th>
<th>Colorado / Total (%) of Participants</th>
<th>Finland / Total (%) of Participants</th>
<th>Germany / Total (%) of Participants</th>
</tr>
</thead>
<tbody>
<tr>
<td>Multiple islet autoantibody–positive</td>
<td>585/13 377 (4.4)</td>
<td>69/1962 (3.5)</td>
<td>399/8597 (4.6)</td>
<td>117/2818 (4.2)</td>
</tr>
<tr>
<td>Girls</td>
<td>249/685 (42.6)</td>
<td>34/69 (49.3)</td>
<td>164/2818 (41.3)</td>
<td>71/117 (43.6)</td>
</tr>
<tr>
<td>Family history of type 1 diabetes</td>
<td>201/585 (34.4)</td>
<td>39/69 (56.5)</td>
<td>45/2818 (13.3)</td>
<td>117/2818 (100)</td>
</tr>
<tr>
<td>HLA DR3/DR4-DQ8</td>
<td>185/577 (32.1)</td>
<td>31/69 (44.9)</td>
<td>119/4488 (25.9)</td>
<td>35/109 (32.1)</td>
</tr>
<tr>
<td>Follow-up time, median (IQR), y</td>
<td>4.5 (2.3–7.2)</td>
<td>5.6 (3.5–7.7)</td>
<td>3.9 (2.2–6.9)</td>
<td>5.3 (2.9–7.7)</td>
</tr>
<tr>
<td>Seroconversion age, median (IQR), y</td>
<td>2.1 (1.3–4.1)</td>
<td>3.1 (1.6–5.4)</td>
<td>2.0 (1.3–4.3)</td>
<td>2.1 (1.1–5.0)</td>
</tr>
<tr>
<td>Nonwhite race/ethnicity</td>
<td>8/585 (1.4)</td>
<td>6/69 (8.7)</td>
<td>0/2818 (0)</td>
<td>2/117 (1.7)</td>
</tr>
<tr>
<td>Single islet autoantibody–positive</td>
<td>474/13 377 (3.5)</td>
<td>71/1962 (3.6)</td>
<td>293/8597 (3.4)</td>
<td>110/2818 (3.9)</td>
</tr>
<tr>
<td>Girls</td>
<td>211/474 (44.5)</td>
<td>34/71 (47.9)</td>
<td>172/2818 (58.7)</td>
<td>110/2818 (110)</td>
</tr>
<tr>
<td>Family history of type 1 diabetes</td>
<td>161/474 (34.0)</td>
<td>35/71 (49.3)</td>
<td>125/2818 (44.9)</td>
<td>110/2818 (110)</td>
</tr>
<tr>
<td>HLA DR3/DR4-DQ8</td>
<td>79/450 (17.8)</td>
<td>20/71 (28.2)</td>
<td>51/276 (18.5)</td>
<td>8/103 (7.8)</td>
</tr>
<tr>
<td>Follow-up time, median (IQR), y</td>
<td>5.5 (2.6–8.5)</td>
<td>5.5 (2.9–7.8)</td>
<td>5.5 (2.4–8.2)</td>
<td>5.9 (2.8–10)</td>
</tr>
<tr>
<td>Seroconversion age, median (IQR), y</td>
<td>4.8 (2.1–7.7)</td>
<td>5.4 (2.6–9.2)</td>
<td>3.9 (2.0–6.5)</td>
<td>7.3 (3.3–9.8)</td>
</tr>
<tr>
<td>Nonwhite race/ethnicity</td>
<td>9/474 (1.9)</td>
<td>7/71 (9.9)</td>
<td>0/2818 (0)</td>
<td>2/110 (1.8)</td>
</tr>
<tr>
<td>Autoantibody negative</td>
<td>12 318/13 377 (92.1)</td>
<td>1822/1962 (92.8)</td>
<td>7005/8597 (91.9)</td>
<td>2591/2818 (91.9)</td>
</tr>
<tr>
<td>Girls</td>
<td>5807/12 318 (47.1)</td>
<td>882/1822 (48.4)</td>
<td>3662/7905 (46.3)</td>
<td>1203/2591 (48.7)</td>
</tr>
<tr>
<td>Family history of type 1 diabetes</td>
<td>NA</td>
<td>629/1822 (34.5)</td>
<td>NA</td>
<td>2591/2591 (100)</td>
</tr>
<tr>
<td>HLA DR3/DR4-DQ8</td>
<td>1200/7298 (16.4)</td>
<td>404/1822 (22.2)</td>
<td>613/4488 (13.7)</td>
<td>183/2188 (8.4)</td>
</tr>
<tr>
<td>Follow-up time, median (IQR), y</td>
<td>8.9 (4.1–12.6)</td>
<td>9.0 (3.3–14)</td>
<td>8.9 (4.3–12.1)</td>
<td>8.2 (4.8–13.5)</td>
</tr>
<tr>
<td>Nonwhite race/ethnicity</td>
<td>204/13 377 (1.5)</td>
<td>164/1822 (9.0)</td>
<td>0/7905 (0)</td>
<td>40/2591 (1.5)</td>
</tr>
</tbody>
</table>

Abbreviations: HLA, human leukocyte antigen; IQR, interquartile range; NA, not available.

*Full HLA DR-DQ genotype was unavailable in 8 children with multiple islet antibodies, 7 children with a single islet autoantibody, and 403 children with no islet autoantibodies from Germany; 17 children with a single islet autoantibody, and 3417 children with no islet autoantibodies from Finland.

*Follow-up time from the age of seroconversion to the age at diabetes or last contact.

©2013 American Medical Association. All rights reserved.

2476 JAMA, June 19, 2013—Vol 309, No. 23

Downloaded From: on 05/07/2018
In total, 48 children (10%) progressed to diabetes (HR compared with children with no autoantibodies, 52.7 [95% CI, 32.4-85.7], *P* < .001) at a median follow-up time after seroconversion of 2.6 years (IQR, 0.6-4.1 years), and a median age of 5.2 years (IQR, 2.9-10 years). Progression to diabetes within 10 years after seroconversion was 14.5% (95% CI, 10.3%-18.7%). Ten-year risks were not significantly different (log-rank test, *P* = .69) across the 3 cohorts: Colorado, 17.7% (95% CI, 4.1%-31.3%); Finland, 13.3% (95% CI, 9.9%-17.7%); Germany, 14.7% (95% CI, 5.1%-25.3%). Progression to diabetes within 10 years was higher in children with IA2 autoantibodies (40.5% [95% CI, 17.7%-63.3%]) than in children with GAD65 autoantibodies (12.9% [95% CI, 5.1%-20.7%], *P* < .001) and children with insulin autoantibodies (13.1% [95% CI, 8.0%-18.2%], *P* = .005) (Figure 3B).

**DISCUSSION**

These data show that the detection of multiple islet autoantibodies in children who are genetically at risk marks a preclinical stage of type 1 diabetes. Only a minority of these children did not develop diabetes for more than a decade regardless of whether they had a family history of type 1 diabetes or a high-risk HLA genotype. Thus, the development of multiple islet autoantibodies in children predicts type 1 diabetes. While most children with multiple islet autoantibodies progressed to diabetes, progression time to diabetes after seroconversion was heterogeneous. In our study, it ranged from weeks to 18 years and has been reported to take more than 2 decades in some individuals. Variation in progression time was associated with the age of seroconversion, genetic markers, sex, and the type of islet autoantibody. A faster rate of progression in children with early seroconversion was previously reported in a subset of the German cohort. Variation in risk depending on islet autoantibody type is consistent with findings in studies using cross-sectional screening to identify patients with islet autoantibodies.

Islet autoantibodies are generally considered markers, rather than mediators, of β-cell dysfunction. Exposure to islet autoantibodies is insufficient to cause disease because maternal transfer of autoantibodies to the fetus does not increase the risk of type 1 diabetes in offspring. Moreover, none of the known islet autoantigens are expressed on the β-cell surface, and no direct effect of islet autoantibodies on β-cell function has been reproducibly observed. However, a pathogenetic role of the autoantibodies cannot be excluded. The observation made in this study that multiple islet autoantibodies are associated with highest risk of type 1 diabetes, together with previous indications that risk is associated

---

**Figure 1. Development of Diabetes in Children Stratified for Islet Autoantibody Outcome**

**Figure 2. Progression to Diabetes From the Time of Seroconversion in Children With Multiple Islet Autoantibodies**

©2013 American Medical Association. All rights reserved.
with the titer of some islet autoantibodies, is consistent with a role in pathogenesis. Autoantigens are released as a consequence of β-cell death, permitting islet autoantibodies to bind and form immune complexes that are likely to promote islet inflammation. Specific islet autoantibody–antigen complexes may also accelerate the spread of autoimmunity to multiple targets via an opsonization-like process. IA2 autoantibodies, which were associated with a higher risk than GAD65 autoantibodies or insulin autoantibodies, may be particularly effective in epitope spreading because they not only bind to IA2 but also to IA2-β, which is also expressed in the β cell and a target autoantigen.

Our study has important limitations. Data on potentially relevant socioeconomic, environmental, and clinical factors were not collected in all 3 studies and could not be included in prediction analyses. It is possible that seroconversions were missed in children who may have had transient circulating autoantibodies between visits. This would mainly have affected estimates from the subset of children in the German study with visit intervals of up to 3 years. Relevant to this limitation, around 10% of children with islet autoantibodies who were screened at intervals of 12 months or less had transient antibodies, and, consistent with a previous report, almost all had single islet autoantibodies. The cohort enrolled only children who were genetically susceptible into follow-up, and entry criteria for islet autoantibody screening differed among the 3 studies. A sizeable portion of type 1 diabetes diagnoses will occur among children with lower genetic risk than those included in the cohort, and a relatively large number of patients with type 1 diabetes are diagnosed in adulthood. Thus, it is possible that the findings may not be generalizable to all presentations of childhood type 1 diabetes and type 1 diabetes in adults.

Type 1 diabetes is currently not preventable in children who develop multiple islet autoantibodies. Our findings highlight the need for research into finding interventions to stop the development of multiple islet autoantibodies and to stop or delay progression to type 1 diabetes. Children with islet autoantibodies who do not develop diabetes for more than 15 years and the factors associated with slower progression (such as sex and age at seroconversion) should also be studied, because it may be helpful for understanding natural protective mechanisms.

### Table 2. Predictors of Type 1 Diabetes After Seroconversion in Children With Multiple Islet Autoantibodies

<table>
<thead>
<tr>
<th>Variable</th>
<th>10-Year Risk, % (95% CI)</th>
<th>Bivariable Hazard Ratio (95% CI)</th>
<th>P Value</th>
<th>Multivariable Hazard Ratio (95% CI)</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Seroconversion age, y</td>
<td>78.7 (69.7-80.1)</td>
<td>1.72 (1.36-2.17)</td>
<td>&lt;.001</td>
<td>1.65 (1.30-2.09)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>≥3</td>
<td>60.9 (51.5-70.3)</td>
<td>1 [Reference]</td>
<td></td>
<td>1 [Reference]</td>
<td></td>
</tr>
<tr>
<td>HLA genotype</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DR3/DR4-DQ8</td>
<td>76.6 (69.2-84.0)</td>
<td>1.40 (1.12-1.73)</td>
<td>.003</td>
<td>1.35 (1.09-1.68)</td>
<td>.007</td>
</tr>
<tr>
<td>Other</td>
<td>66.2 (60.2-72.2)</td>
<td>1 [Reference]</td>
<td></td>
<td>1 [Reference]</td>
<td></td>
</tr>
<tr>
<td>Sex</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Girls</td>
<td>74.8 (68.0-81.6)</td>
<td>1.30 (1.05-1.60)</td>
<td>.02</td>
<td>1.28 (1.04-1.58)</td>
<td>.02</td>
</tr>
<tr>
<td>Boys</td>
<td>65.7 (59.3-72.1)</td>
<td>1 [Reference]</td>
<td></td>
<td>1 [Reference]</td>
<td></td>
</tr>
<tr>
<td>No. of autoantibodies</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>72.1 (66.5-77.7)</td>
<td>1.27 (1.02-1.59)</td>
<td>.04</td>
<td>1.19 (0.95-1.49)</td>
<td>.14</td>
</tr>
<tr>
<td>2</td>
<td>65.1 (66.3-73.9)</td>
<td>1 [Reference]</td>
<td></td>
<td>1 [Reference]</td>
<td></td>
</tr>
</tbody>
</table>

*Multivariable hazard ratio includes all listed variables (seroconversion age, human leukocyte antigen genotype, sex, number of autoantibodies).

### Figure 3. Progression to Diabetes in Children From the Time of Seroconversion According to Islet Autoantibody Type

![Diagram](A) Two islet autoantibodies

- IAA + IA2
- IAA + GAD65
- IA2 + GAD65

![Diagram](B) Single islet autoantibodies

- IAA
- IA2
- GAD65

IAA indicates insulin autoantibodies; IA2, insulinoma antigen 2 autoantibodies; and GAD65, glutamic acid decarboxylase 65 autoantibodies. The numbers at risk represent the children receiving follow-up at year 0, 5, 10, and 15.
CIRCULATING ISLET ANTIBODIES AND DIABETES IN CHILDREN

Author Affiliations: Institute of Diabetes Research, Helmholtz Zentrum München, and Forschungsgruppe Diabetes, Klinikum rechts der Isar, Technische Universität München, Neuenberg, Germany (Dr Ziegler and Winkel); Barbara Davis Center for Childhood Diabetes, University of Colorado School of Medicine, Aurora (Drs Rewers, Steck, and Eisenbarth); Department of Pediatrics (Drs O. Simell, T. Simell, and Lempainen) and Immunogenetics Laboratory (Dr Lempainen and Ilenen), University of Turku, and Department of Pediatrics, Turku University Hospital (Drs O. Simell, T. Simell, and Lempainen), Turku, Finland; Department of Clinical Microbiology, University of Eastern Finland, Kuopio, Finland (Dr Ilenen); Department of Pediatrics, Institute of Clinical Medicine, University of Oulu, Oulu, Finland (Dr Veijola); Children’s Hospital, University of Helsinki and Helsinki University Central Hospital, Helsinki, and Department of Pediatrics, Tampere University Hospital, Tampere, Finland (Dr Knip); Center for Regenerative Therapies Dresden, and Paul Langerhans Institute Dresden, German Center for Diabetes Research, Dresden University of Technology, Dresden, Germany (Dr Bonifacio).

Author Contributions: Dr Ziegler had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Drs Ziegler, Rewers, and O. Simell had equal contribution as first authors.

Study concept and design: Drs Ziegler, Rewers, O. Simell, T. Simell, Ilenen, Veijola, Bonifacio.


Obtained funding: Ziegler, Rewers, O. Simell, Ilenen, Veijola, Knip, Bonifacio.

Statistical analysis: Ziegler, Rewers, Lempainen, Winkel, Veijola, Bonifacio.

Study supervision: Ziegler, Rewers, O. Simell, Ilenen, Veijola, Knip, Bonifacio.

Conflict of Interest Disclosures: All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Ziegler reports receiving grant funding from the Juvenile Diabetes Research Foundation International, Deutsche Forschungsgemeinschaft, and Bundesministerium für Bildung und Forschung, Dr O. Simell reports receiving grant funding from the Juvenile Diabetes Research Foundation Foundation International. Dr Steck reports receiving grant support from the National Institutes of Health. Dr Veijola reports receiving grant support from the Juvenile Diabetes Research Foundation and Oulu University Hospital Research funds, and funding for travel from the Juvenile Diabetes Research Foundation; and serving as board member for Nuevo Nordisk Diabetes, Finland, and Medtronic Nordic; and having pending grants from the National Institutes of Health for the Environmental Determinants of Diabetes in the Young (TEDDY) and the Trial to Reduce Insulin-Dependent Diabetes Mellitus in the Genetically at Risk (TRIGR) international studies, Alma and K.A. Snellman Foundation, and the Foundation for Pediatric Research, Finland. Dr Bonifacio reports receiving grant funding from the Juvenile Diabetes Research Foundation. No other financial disclosures were reported.

Funding/Support: Primary support for this work was provided by grants 1-1-2000-619 (BABYDIAB) and 4-1999-731 and 4-2001-435 (DIPP) from the Juvenile Diabetes Research Foundation; R01 DK32493 (DAISY) from the National Institutes of Health; and KD99999 (DAIRDIA) from Bundesministerium für Bildung und Forschung; and ZI-310/14-1, ZI-310/14-2, ZI-310/14-3, and ZI-310/14-4 (BABYDIET) from Deutsche Forschungsgemeinschaft.

Role of the Sponsor: The Juvenile Diabetes Research Foundation, National Institutes of Health, Bundesministerium für Bildung und Forschung, and Deutsche Forschungsgemeinschaft had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Additional Contributions: We thank Fran Dong, MS (Barbara Davis Center for Childhood Diabetes, University of Colorado), and Andreas Beyerlein, PhD (Institute of Diabetes Research, Helmholtz Zentrum München), for statistical analyses. Ms Dong and Dr Beyerlein did not receive additional compensation.

REFERENCES